BRITISH MEDICAL JOURNAL

SATURDAY 26 MARCH 1983

LEADING ARTICLES	·
Non-hormonal treatment of osteoporosis ALLAN ST J DIXON Laser photocoagulation of senile macular degeneration A C BII Intestinal anastomosis I E GILLESPIE	rd 1001
CLINICAL RESEARCH • PAPERS AND SED Digital vascular imaging and selective renin sampling in evaluation of various selective renin sampling in evaluation selective renin sampling in evaluation selective renin sampling selective renin selective	
G A KHOURY, J D IRVING, K FARRINGTON, Z VARGHESE, J W PERSAUD, P ST	weny, j f moorhead, o n fernando
Cardiac complications of carbamazepine intoxication: treatment by ha	RINGTON, P D HARRIS, T WHEELER 1009 s TIM HIGENBOTTAM, T C STOKES, S JAMIESON, L HILL 1012 P G F SWIFT, J D KENNEDY, L S GERLIS 1015 NE, R P STOKES, R A THOMPSON 1015 six days HUNG K CHEUNG, EDWIN C S YU 1016 aralysed newborn babies 1017 aemoderfusion P I LESLIE, R HEYWORTH, L F PRESCOTT 1018
Law and the General Practitioner: Statutory sick pay: it will affect your Overlapping with General Practice: Probation officer JDRTODD	NATIONAL AGRICULTURAL LIBRARY 1021 RECEIVED
MEDICAL PRACTICE	APR 1 2 1983
Spring Books	PROGUREMENT SECTION
Medical sense and nonsense in biography MILO KEYNES 1023 100 years of information on drugs DOUGLAS WHITTET 1032 Opposing traditional view of medicine EDWARD HARE 1034 Life in a Welsh valley WILLIAM EVANS 1035 Cur urceus exit? RUTH HOLLAND	Buying British: an Oxford initiative ENT SERIAL NECOPOSITION INTRODUCTION TESSA RICHARDS 1027 Clearing the jungle of medical education JD SWALES 1028 Overcoming prejudice JOHN LAUNER 1029 A bird's eye view PHILIP EVANS 1030 Jewel of scholarship ALEX PATON 1030
ABC of Healthy Travel: First aid while abroad ERIC WALKER, GLYN W New Drugs: Beta-blockers and sympathomimetics JOHN FEELY, PHILL Letters to a Young Doctor: Overseas doctors PHILIP RHODES Any Questions? Medicine and the Media—Contributions from KENNETH C CALMAN, S BE Personal View JOHN CROFTON Correction: Polychlorinated biphenyls (Any Questions)	.IP J de VANE, DEREK MACLEAN
CORRESPONDENCE—List of Contents	BMA ANNUAL REPORT OF COUNCIL 1982-3 Separately paginated in centre
OBITUARY 1068	SUPPLEMENT
NEWS AND NOTES Views	The Week
BMA Notices	committee discusses draft

CORRESPONDENCE

Adverse reactions to new drugs G R Venning, FRCP; A Herxheimer, FRCP, and O Hansson, MD	Writer's cramp C D Marsden, FRCP, FRS	Repeated renal failure associated with captopril Judith A Whitworth, FRACP, and Priscilla Kincaid-Smith, FRACP
Why one should not take the MRCGP examination J A Kerr, MRCGP; J L Ogle, MB; Anna S Wilson, MRCGP; J Birch	insulin dependent diabetics R Worth, MRCP, and others	Mary C Brown, MB
A Z S Rohatiner, MRCP, and others; N B Finter, MRCP, and D S Freestone, MB 1054 Competitive spectacles R P Crick, FRCS	malformation of the inner ear N P von Haacke, FRCS, and C B Croft, FRCS 1058 Leg ulcers that do not heal M J Callam, FRCSED, and others	Hours of work of junior doctors A Bristow, MB
Erythrapheresis in polycythaemia R J Gregory, MRCP 1056 Personality and socks C H Shaw, FFCM 1056 Computed tomography in the investigation of dementia P Manu, MD 1056 Calcium antagonist withdrawal syndrome Julia V Nehring, and A J Camm, MRCP 1057	ranitidine D Rowley-Jones, MRCP, and A C Flind, BM 1059 Acquired immune deficiency syndrome A G Lawrence, MB	Points Serum creatinine and renal function in rheumatic disease (P Sogaard); Malaria prophylaxis (S S Bakhshi); Recurrent aphthous ulceration (D A Fenton, and others); Late development of incisional hernia (T Gledhill); Effects of smoking on long term patency of arteriovenous fistulas (C V Clark); Wanted: psychiatrists with an interest in mental illness (B H Hicks) . 106

We may return unduly long letters to the author for shortening so that we can offer readers as wide a selection as possible. We receive so many letters each week that we have to omit some of them. Letters should be typed with double spacing between lines and must be signed personally by all their authors, who should include their degrees. Letters critical of a paper may be sent to the authors of the paper so that their reply may appear in the same issue.

Correspondents should present their references in the Vancouver style (see examples in these columns). In particular, the names and initials of all authors must be given unless there are more than six, when only the first three should be given, followed by et al; and the first and last page numbers of articles and chapters should be included.

Adverse reactions to new drugs

SIR,-Dr W H W Inman (26 February, p 719) defends loyally the yellow cards he left behind when he moved to Southampton to explore a different approach. His arguments for exonerating the yellow card failures to provide first alerts for lincomycin, clindamycin, stilboestrol, and aerosols are unconvincing in the light of the references cited, the relevant dates, and the delays to regulatory action. We agree about the three practolol reactions (and about subacute myelo-optic neuropathy, for which causality was unproved). Thus the yellow cards failed to provide first alerts for seven reactions to five drugs in table I all occurring after the start of the system in 1964. I have no evidence, however, that the yellow cards provided first alerts to any of the 48 other reactions to 56 drugs identified as important in tables II and III in part I (15 January, p 199). A number of these were also identified after 1964. Further detailed analysis of this unbiased list would provide a valid method for auditing the system in operation.

Dr Inman also refers to "hundreds of signals... and many serious problems quietly and efficiently attended to...." If none of these have been identified by any one of 20 doctors, including Dr Inman himself, as important (as defined) then it seems inescapable

that the yellow cards are better at identifying less important reactions and less effective at providing first alerts to the most serious reactions, which are usually very infrequent. This is precisely what might be predicted on general common sense grounds and on review of the yellow card files, in which there is a marked preponderance of reactions that are already known and very large numbers of minor reactions which have clogged up the system for reading and assessing the reports.

For the specific purpose of first alerting I proposed, when working at the Department of Health and Social Security, that it would be far more efficient to employ someone to read the published work and to base yellow peril letters to the medical profession and warnings in Current Problems on the first alerts and first verifications from the journals which have in the past almost always preceded the first regulatory warnings based on yellow card data. This is now happening and should yield a better return on the investment, particularly in terms of prompt alerting of the medical profession in the publications of the Committee on the Safety of Medicines.

Dr Inman made a number of important contributions at the DHSS, whose value was mainly dependent on his sound epidemiological approach and his reliance on valid methods that have little or nothing to do with yellow cards. He is, in fact, to be congratulated on what he achieved in spite of the indisputable weaknesses of the system. Firstly, he conducted a number of formal verification studies using a case orientated approach along the lines proposed in my conclusions to the series (12 February, p 544). Secondly, he was careful to validate yellow card reports, using the part time medical officers employed by the DHSS. This important safeguard was not in operation recently. Thirdly, his work on the pill and thromboembolism included analysis of death certificates. Unlike the yellow cards these provide an unbiased data base suitable for case control studies. Fourthly, his work on the pill and myocardial infarction was critically dependent for its value on the analysis of dose response data. This is only applicable to a minority of adverse reaction problems and provides, as pointed out, one of the only ways of using for verification of suspected reactions a system that is fundamentally flawed in epidemiological terms.

On a general note the data available to the Committee on the Safety of Medicines, which form the basis of "serious problems quietly and efficiently attended to," are not usually